{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:48:53Z","timestamp":1762177733444,"version":"3.44.0"},"reference-count":66,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Despite advancements in genetic testing and expanded eligibility criteria, underutilisation of germline testing for pathogenic variants in BRCA1 and BRCA2 (BRCA) remains evident among breast cancer (BC) patients. This observational cohort study presents real-world data on BRCA testing within the context of clinical practice challenges, including incomplete family history and under-referral.\nMaterial and methods: From the Danish Breast Cancer Group (DBCG) clinical database, we included 65,117 females with unilateral stage I\u2013III BC diagnosed in 2000\u20132017, of whom 9,125 (14%) were BRCA tested. Test results spanned from 1999 to 2021. We evaluated test rates overall and in three diagnosis periods. In logistic regression models, we examined the correlation between a BRCA test and patients\u2019 age, residency region, receptor status, and diagnosis period.\nResults: Test rates rose most significantly among patients aged under 40 years, increasing from 47% (2000\u20132005) to 88% (2012\u20132017), albeit with regional discrepancies. Test timing shifted in recent years, with most results within 6 months of BC diagnosis, primarily among the youngest patients. BRCA test rates were higher for oestrogen receptor-negative\/human epidermal growth factor receptor 2-negative BC (25% in 2000\u20132005 vs. 38% in 2012\u20132017), and these findings were confirmed in multivariate regression models.\nInterpretation: Our results indicate a critical need for an intensified focus on BRCA testing among BC patients older than 40, where a mainstreamed testing approach might overcome delayed or missed testing. Current DBCG guidelines recommend BRCA testing of all BC patients younger than 50 years, while a general recommendation for older patients is still missing.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.42418","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T02:56:17Z","timestamp":1738119377000},"page":"147-155","source":"Crossref","is-referenced-by-count":2,"title":["Germline BRCA testing in Denmark following invasive breast cancer: Progress since 2000"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5034-8597","authenticated-orcid":false,"given":"Aleksandar M.","family":"Kostov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-3040","authenticated-orcid":false,"given":"Maj-Britt","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8761-714X","authenticated-orcid":false,"given":"Bent","family":"Ejlertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4325-3027","authenticated-orcid":false,"given":"Caroline Maria","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-8040","authenticated-orcid":false,"given":"Inge S.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-6942","authenticated-orcid":false,"given":"Annabeth H.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-3068","authenticated-orcid":false,"given":"Lise Lotte","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2882-6798","authenticated-orcid":false,"given":"Karin A.W.","family":"Wadt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-8686","authenticated-orcid":false,"given":"Anne-Vibeke","family":"L\u00e6nkholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Tung NM, Garber JE. BRCA1\/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018;119(2):141\u201352.","key":"96855","DOI":"10.1038\/s41416-018-0127-5"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41416-018-0127-5","key":"96856","DOI":"10.1038\/s41416-018-0127-5"},{"doi-asserted-by":"crossref","unstructured":"Breast Cancer Risk Genes \u2013 Association analysis in more than 113,000 women. N Engl J Med. Massachusetts Medical Society; 2021;384(5):428\u201339.","key":"96857","DOI":"10.1056\/NEJMoa1913948"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1913948","key":"96858","DOI":"10.1056\/NEJMoa1913948"},{"doi-asserted-by":"crossref","unstructured":"Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440\u201351.","key":"96859","DOI":"10.1056\/NEJMoa2005936"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2005936","key":"96860","DOI":"10.1056\/NEJMoa2005936"},{"doi-asserted-by":"crossref","unstructured":"Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balma\u00f1a J, Pat\u00f3cs AB, et al. Overview of hereditary breast and ovarian cancer (HBOC) guide-lines across Europe. Eur J Med Genet. 2021;64(12):104350.","key":"96861","DOI":"10.1016\/j.ejmg.2021.104350"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejmg.2021.104350","key":"96862","DOI":"10.1016\/j.ejmg.2021.104350"},{"doi-asserted-by":"crossref","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for brca1 and brca2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","key":"96863","DOI":"10.1001\/jama.2017.7112"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jama.2017.7112","key":"96864","DOI":"10.1001\/jama.2017.7112"},{"doi-asserted-by":"crossref","unstructured":"Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, et al. Frequency of Contralateral prophylactic mastectomy in breast cancer patients with a negative BRCA1 and BRCA2 rapid genetic test result. Ann Surg Oncol. 2021;28(9):4967\u201373.","key":"96865","DOI":"10.1245\/s10434-021-09855-6"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1245\/s10434-021-09855-6","key":"96866","DOI":"10.1245\/s10434-021-09855-6"},{"unstructured":"DMCG.dk [Internet]. DBCG guidelines for Hereditary Breast Cancer, Dec 2022. Available from: https:\/\/www.dmcg.dk\/siteassets\/kliniske-retningslinjer---skabeloner-og-vejledninger\/kliniske-retningslinjer-opdelt-pa-dmcg\/dbcg\/dbcg_arvelig-cancer-mamma_v.2.0_admgodk_02012023.pdf","key":"96867"},{"doi-asserted-by":"crossref","unstructured":"Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, et al. Germline testing in patients with breast cancer: ASCO\u2013Society of Surgical Oncology Guideline. J Clin Oncol. 2024;42(5):584\u2013604.","key":"96868","DOI":"10.1200\/JCO.23.02225"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.23.02225","key":"96869","DOI":"10.1200\/JCO.23.02225"},{"doi-asserted-by":"crossref","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2024;35(2):159\u201382.","key":"96870","DOI":"10.1016\/j.annonc.2023.11.016"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016","key":"96871","DOI":"10.1016\/j.annonc.2023.11.016"},{"doi-asserted-by":"crossref","unstructured":"Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023;34(11):970\u201386.","key":"96872","DOI":"10.1016\/j.annonc.2024.11.001"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2023.08.017","key":"96873","DOI":"10.1016\/j.annonc.2023.08.017"},{"doi-asserted-by":"crossref","unstructured":"Grindedal EM, J\u00f8rgensen K, Olsson P, Gravdehaug B, Lur\u00e5s H, Schlichting E, et al. Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway. Fam Cancer. 2020;19(2):133\u201342.","key":"96874","DOI":"10.1007\/s10689-020-00160-x"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10689-020-00160-x","key":"96875","DOI":"10.1007\/s10689-020-00160-x"},{"doi-asserted-by":"crossref","unstructured":"Grindedal EM, Heramb C, Karsrud I, Ariansen SL, M\u00e6hle L, Undlien DE, et al. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer. 2017;17(1):438.","key":"96876","DOI":"10.1186\/s12885-017-3422-2"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12885-017-3422-2","key":"96877","DOI":"10.1186\/s12885-017-3422-2"},{"doi-asserted-by":"crossref","unstructured":"Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453\u201360.","key":"96878","DOI":"10.1200\/JCO.18.01631"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.18.01631","key":"96879","DOI":"10.1200\/JCO.18.01631"},{"doi-asserted-by":"crossref","unstructured":"Meshkani Z, Aboutorabi A, Moradi N, Langarizadeh M, Motlagh AG. Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. Hered Cancer Clin Pract. 2021;19(1):35.","key":"96880","DOI":"10.1186\/s13053-021-00191-0"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13053-021-00191-0","key":"96881","DOI":"10.1186\/s13053-021-00191-0"},{"doi-asserted-by":"crossref","unstructured":"Rajagopal PS, Catenacci DVT, Olopade OI. The time for mainstreaming germline testing for patients with breast cancer is now. J Clin Oncol. 2019;37(24):2177\u20138.","key":"96882","DOI":"10.1200\/JCO.19.00160"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.19.00160","key":"96883","DOI":"10.1200\/JCO.19.00160"},{"doi-asserted-by":"crossref","unstructured":"Nilsson MP, Winter C, Kristoffersson U, Rehn M, Larsson C, Saal LH, et al. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. Fam Cancer. 2017;16(2):187\u201393.","key":"96884","DOI":"10.1007\/s10689-016-9953-x"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10689-016-9953-x","key":"96885","DOI":"10.1007\/s10689-016-9953-x"},{"doi-asserted-by":"crossref","unstructured":"Li J, Wen WX, Eklund M, Kvist A, Eriksson M, Christensen HN, et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. Int J Cancer. 2019;144(5):1195\u2013204.","key":"96886","DOI":"10.1002\/ijc.31841"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ijc.31841","key":"96887","DOI":"10.1002\/ijc.31841"},{"doi-asserted-by":"crossref","unstructured":"Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, et al. Time trends in receipt of germline genetic testing and results for women diag-nosed with breast cancer or ovarian cancer, 2012-2019. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(15):1631\u201340.","key":"96888","DOI":"10.1200\/JCO.20.02785"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.20.02785","key":"96889","DOI":"10.1200\/JCO.20.02785"},{"doi-asserted-by":"crossref","unstructured":"Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800\u20136.","key":"96890","DOI":"10.1200\/JCO.2017.73.6314"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2017.73.6314","key":"96891","DOI":"10.1200\/JCO.2017.73.6314"},{"doi-asserted-by":"crossref","unstructured":"Christiansen P, Ejlertsen B, Jensen M-B, Mouridsen H. Danish Breast Cancer Cooperative Group. Clin Epidemiol. 2016;8:445\u20139.","key":"96892","DOI":"10.2147\/CLEP.S99457"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S99457","key":"96893","DOI":"10.2147\/CLEP.S99457"},{"doi-asserted-by":"crossref","unstructured":"Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health. 2011;39(7_suppl):72\u20134.","key":"96894","DOI":"10.1177\/1403494810393563"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1403494810393563","key":"96895","DOI":"10.1177\/1403494810393563"},{"doi-asserted-by":"crossref","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u201390.","key":"96896","DOI":"10.2147\/CLEP.S91125"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S91125","key":"96897","DOI":"10.2147\/CLEP.S91125"},{"doi-asserted-by":"crossref","unstructured":"Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39(7 Suppl):42\u20135.","key":"96898","DOI":"10.1177\/1403494810393562"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1403494810393562","key":"96899","DOI":"10.1177\/1403494810393562"},{"doi-asserted-by":"crossref","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31\u20134.","key":"96900","DOI":"10.4103\/sja.SJA_543_18"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/sja.SJA_543_18","key":"96901","DOI":"10.4103\/sja.SJA_543_18"},{"doi-asserted-by":"crossref","unstructured":"Pedersen IS, Schmidt AY, Bertelsen B, Ernst A, Andersen CLT, Kruse T, et al. A Danish national effort of BRCA1\/2 variant classification. Acta Oncol. 2018;57(1):159\u201362.","key":"96902","DOI":"10.1080\/0284186X.2017.1400693"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2017.1400693","key":"96903","DOI":"10.1080\/0284186X.2017.1400693"},{"doi-asserted-by":"crossref","unstructured":"Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic Health Registry-based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533\u201354.","key":"96904","DOI":"10.2147\/CLEP.S314959"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S314959","key":"96905","DOI":"10.2147\/CLEP.S314959"},{"doi-asserted-by":"crossref","unstructured":"Hooker GW, Clemens KR, Quillin J, Vogel Postula KJ, Summerour P, Nagy R, et al. Cancer genetic counseling and testing in an era of rapid change. J Genet Couns. 2017;26(6):1244\u201353.","key":"96906","DOI":"10.1007\/s10897-017-0099-2"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10897-017-0099-2","key":"96907","DOI":"10.1007\/s10897-017-0099-2"},{"doi-asserted-by":"crossref","unstructured":"Gronwald J, Cybulski C, Huzarski T, Jakubowska A, Debniak T, Lener M, et al. Genetic testing for hereditary breast cancer in Poland: 1998\u20132022. Hered Cancer Clin Pract. 2023;21:9.","key":"96908","DOI":"10.1186\/s13053-023-00252-6"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13053-023-00252-6","key":"96909","DOI":"10.1186\/s13053-023-00252-6"},{"doi-asserted-by":"crossref","unstructured":"Thomassen M, Hansen TVO, Borg \u00c5, Theilmann Lianee H, Wikman F, S\u00f8kilde Pedersen I, et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and\/or ovarian cancer. Acta Oncol. 2008;47(4):772\u20137.","key":"96910","DOI":"10.1080\/02841860802004974"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/02841860802004974","key":"96911","DOI":"10.1080\/02841860802004974"},{"unstructured":"DBCG.dk [Internet]. DBCG guidelines for Hereditary Breast Cancer, Sept 2016. Available from: https:\/\/dbcg.dk\/PDF%20Filer\/Kapitel_19_HBOC_23.09.2016.pdf","key":"96912"},{"doi-asserted-by":"crossref","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomark Prev. 2012;21(1):134\u201347.","key":"96913","DOI":"10.1016\/j.yobg.2012.05.049"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1055-9965.EPI-11-0775","key":"96914","DOI":"10.1158\/1055-9965.EPI-11-0775"},{"doi-asserted-by":"crossref","unstructured":"Tomasello G, Gambini D, Petrelli F, Azzollini J, Arcan\u00e0 C, Ghidini M, et al. Characterization of the HER2 status in BRCA-mutated breast cancer: a single institu-tional series and systematic review with pooled analysis. ESMO Open. 2022;7(4):100531.","key":"96915","DOI":"10.1016\/j.esmoop.2022.100531"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100531","key":"96916","DOI":"10.1016\/j.esmoop.2022.100531"},{"doi-asserted-by":"crossref","unstructured":"Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, et al. Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. Breast. 2022;65:145\u201350.","key":"96917","DOI":"10.1016\/j.breast.2022.07.012"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.breast.2022.07.012","key":"96918","DOI":"10.1016\/j.breast.2022.07.012"},{"doi-asserted-by":"crossref","unstructured":"Geyer CE, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250\u201368.","key":"96919","DOI":"10.1016\/j.annonc.2022.09.159"},{"doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2022.09.159","key":"96920","DOI":"10.1016\/j.annonc.2022.09.159"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/42418\/48941","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/42418\/48941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:04:56Z","timestamp":1756404296000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/42418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":66,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.42418","relation":{},"ISSN":["1651-226X"],"issn-type":[{"type":"electronic","value":"1651-226X"}],"subject":[],"published":{"date-parts":[[2025,1,28]]}}}